Daito, Japan

Akemi Kuromiya

This inventor holds 1 USPTO granted patent. Top assignee: Dainippon Pharmaceutical Company, Limited. Active years: 2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akemi Kuromiya. Retrieved from https://idiyas.com/inventor/akemi-kuromiya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Akemi Kuromiya: Innovator in Elastase-Inhibiting Compounds

Introduction

Akemi Kuromiya is a notable inventor based in Daito, Japan. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that exhibit elastase-inhibiting activity. Her work is crucial in the pursuit of therapeutic agents that can combat various diseases.

Latest Patents

Kuromiya holds a patent for "Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof." This patent describes heterocyclic compounds represented by a specific general formula, which possess elastase-inhibiting properties. The compounds can be modified with various substituents, enhancing their potential therapeutic applications.

Career Highlights

She is currently employed at Dainippon Pharmaceutical Company, Limited, where she continues her research and development efforts. Her innovative work has positioned her as a key figure in her field, contributing to advancements in drug development.

Collaborations

Throughout her career, Kuromiya has collaborated with esteemed colleagues such as Ryotaro Shiratake and Fuminori Sato. These partnerships have fostered a collaborative environment that enhances the research output and innovation within her team.

Conclusion

Akemi Kuromiya's contributions to the field of elastase-inhibiting compounds highlight her role as a pioneering inventor. Her work not only advances scientific knowledge but also holds promise for future therapeutic developments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…